Can You Bank Your Own Stem Cells? An Honest Guide
Published July 30, 2026 · By Dr. Robert J. Troell, Board-Certified Facial Plastic Surgeon
Dr. Robert J. Troell, MD, FACS
Can You Bank Your Own Stem Cells?
Yes — you can have a small sample of your own fat collected, processed at a specialized laboratory, and cryogenically stored for later use. That is what adipose stem cell banking is. What it is not is a treatment, a cure, or an FDA-approved therapy, and the gap between those two sentences is where most of the confusion lives.
Las Vegas is the combat-sports capital of the world. Every July, International Fight Week fills the city with athletes, coaches, and fans, and with them comes a familiar conversation: fighters talking about “banking” their own cells against the wear that a career of blunt-force impact leaves behind. You do not have to step into an octagon for the underlying question to apply to you. Joint wear, slow-healing wounds, and the volume your face loses over decades are ordinary problems, and the resource being discussed is one your body already carries. Be clear on where each of those stands, though: restoring facial and body volume with your own fat is established surgical work, while the orthopedic and wound-healing uses are still investigational — a distinction this guide keeps throughout.
This guide walks through what banking actually involves, what the federal regulation genuinely says (it is routinely misquoted, including by clinics that should know better), where adipose-derived cells are already used in cosmetic surgery today, where they are still investigational, and what banking honestly cannot promise you.
Wondering Whether Banking Makes Sense for You?
Dr. Robert J. Troell offers private consultations to walk through candidacy, the collection appointment, and what the current evidence does and does not support.
What Stem Cell Banking Actually Is
Banking is storage, not treatment. A small volume of your own fat is collected, sent to a specialized laboratory, and the regenerative cell population within it is isolated, characterized, and frozen under controlled conditions so it can be retrieved years later.
The savings-account comparison gets used a lot, and it is roughly right: you are setting something aside now, in the condition it is in now, on the assumption you may want it later. The comparison breaks down in one important way, though. A dollar deposited today is a dollar in thirty years. A cell is a living thing, and whether it retains its ability to do useful work in storage is a laboratory question with a laboratory answer — which is why the assays a bank runs matter more than its marketing does.
The sequence is consistent across reputable programs: collect a small fat sample, ship it under controlled conditions, isolate the cell population from the tissue, confirm what has actually been isolated and in what quantity, then cryopreserve with documented chain of custody linking every vial to you. Some laboratories also culture-expand the isolated cells to increase their number — a step with real regulatory consequences that we come back to below, because it is the single most misrepresented part of this whole subject.
None of that is the same as a treatment plan. Banking answers “can I keep this?” It does not answer “will this fix my knee in 2041?”
Why Fat, and Not Bone Marrow
For decades, bone marrow was the assumed source of adult stem cells for regenerative work. That assumption shifted in 2001, when a research team at UCLA showed that ordinary human fat — the kind removed during routine liposuction — contains a multipotent cell population of its own.
The paper is worth naming precisely, because it is the foundation for everything that follows. Zuk and colleagues processed human adipose tissue obtained by suction-assisted lipectomy into what they called a processed lipoaspirate, and demonstrated that those cells could be maintained in culture with stable population doubling and could differentiate along adipogenic, chondrogenic, myogenic, and osteogenic lines (Zuk PA, Zhu M, Mizuno H, et al. Tissue Eng. 2001;7(2):211–228. DOI 10.1089/107632701300062859). Their stated motivation was practical rather than theoretical: bone marrow procurement has real limitations, and the field needed an autologous source obtainable in large quantities, under local anesthesia, with minimal discomfort.
Fat is exactly that. It is abundant, it is reachable through a small cannula under local anesthesia, and it is unambiguously yours — no donor, no placental or fetal tissue, no immunological question to answer. That accessibility is why adipose-derived cells moved from a laboratory curiosity to a routine part of aesthetic surgery in roughly two decades, and it is why the same tissue that gets discarded during a liposuction procedure is now treated as a resource in its own right.
It is also why the surgical skill involved is not incidental. Harvesting fat that will be grafted or banked is not the same as harvesting fat to be thrown away: the cannula, the pressure, the processing, and the handling all affect what survives. Dr. Troell wrote the two reference chapters on precisely this in Stem Cells in Aesthetic Procedures: Art, Science, and Clinical Techniques (Springer Berlin Heidelberg, 2014) — one on harvesting, processing, and administration (pp. 249–292. DOI 10.1007/978-3-642-45207-9_18), one on therapeutic uses (pp. 343–363. DOI 10.1007/978-3-642-45207-9_24).
What the FDA Rule Actually Says (and What It Does Not)
There is no FDA-approved adipose stem cell therapy for cosmetic or orthopedic use. Any clinic advertising one is either confused or hoping you are. What exists is something narrower and more interesting: a regulatory lane in which certain autologous tissue products do not require premarket approval at all.
That lane is defined at 21 CFR 1271.10(a). A human cell or tissue product is regulated solely under Section 361 of the Public Health Service Act — meaning no premarket application, no approval — if it meets all four of these criteria, quoted from the current Code of Federal Regulations:
| Criterion | What the regulation requires |
|---|---|
| 1271.10(a)(1) | The product is minimally manipulated. |
| 1271.10(a)(2) | It is intended for homologous use only, as reflected by labeling, advertising, or other indications of the manufacturer’s objective intent. |
| 1271.10(a)(3) | Manufacture does not involve combining the cells or tissue with another article, except water, crystalloids, or a sterilizing, preserving, or storage agent. |
| 1271.10(a)(4) | Either it has no systemic effect and does not depend on the metabolic activity of living cells — or it does, and is for autologous use (or use in a close blood relative, or reproductive use). |
Read that carefully, because the distinction is the whole ballgame. Meeting these criteria is an exemption from premarket approval. It is not an approval. “FDA-compliant under 21 CFR 1271.10(a)” is an accurate description of a same-day, minimally manipulated, autologous fat graft. “FDA-approved stem cell treatment” is not an accurate description of anything in this field, and the FDA has issued warning letters over exactly that wording.
The nuance most consumer articles skip: culture expansion changes the category. Cells that are grown and multiplied in a laboratory are generally considered more than minimally manipulated, which takes them out of the Section 361 lane and into the Section 351 biologic-drug pathway, where clinical use requires the appropriate FDA authorization. So a banked, laboratory-expanded cell product and a same-day fat graft performed in an operating room are two different regulatory objects, even though they came from the same patient and the same tissue. Anyone who tells you otherwise is flattening a distinction the FDA does not flatten.
Side by side, the two pathways look like this:
| Section 361 HCT/P | Section 351 biologic | |
|---|---|---|
| Typical example | Same-day autologous fat grafting; minimally manipulated stored tissue | Laboratory culture-expanded cell product |
| Degree of manipulation | Minimal — rinsing, sizing, cryopreservation | More than minimal — expansion in culture, enzymatic processing |
| Intended use | Homologous only — the tissue does the same job it did originally (fat providing structure and volume) | May be non-homologous |
| Premarket approval | Not required — establishment registration and product listing instead | Required — investigational authorization for trials, licensure to market |
What a Legitimate Bank Has to Do
The laboratory is doing the part you cannot see, in a facility you will never visit, over a timeframe measured in years. That makes its standards the most important thing you can evaluate — and the easiest thing for a marketing page to gloss over.
Dr. Troell’s practice works with American Cell Technologies in Sunrise, Florida, for processing, expansion, and cryostorage. Here is what a facility operating at that standard is expected to maintain:
| Standard | Why it exists |
|---|---|
| Good Manufacturing Practice / Good Tissue Practice facility | The regulatory baseline for handling human cells and tissue; governs everything from air handling to record retention. |
| Certified clean room processing | Isolation of your sample from airborne contamination during the hours it spends open. |
| Per-sample bacterial testing | Contamination is not always visible. Every sample is tested, not a batch representative. |
| Validated expansion methods | “We grew more cells” means nothing without a validated, repeatable method behind it. |
| Chain-of-custody records | Ties every stored vial to the correct patient. This is the safeguard that makes the whole model trustworthy. |
| Flow cytometry + tri-differentiation assays | Confirms what was actually stored, and that the cells retain the ability to differentiate — the difference between storing cells and storing an assumption. |
| 170–200 micron filtration for intravenous delivery | A physical safeguard against cell clumps entering the bloodstream, required any time cells are given intravenously. |
One clarification worth making, because it is commonly muddled: Florida law permits certain non-FDA-approved stem cell treatments within a physician’s scope of practice for a limited set of purposes. That statute governs the laboratory’s operations in Florida. It does not extend a treatment pathway to a patient being treated in Nevada, and it should not be presented as a benefit to you. What matters for a Nevada patient is the federal framework above and the standards the lab actually holds itself to.
What the Collection Appointment Involves
The collection itself is the least dramatic part of banking. It is a short, local-anesthesia office procedure — closer to a very small liposuction than to surgery in any meaningful sense.
It starts with a consultation reviewing your health history, medications, and goals, because candidacy is a medical judgment and not a checkbox. The collection that follows takes roughly twenty minutes and removes about 25 to 50 cc of fat — two to three tablespoons — through a small cannula under local anesthesia. Most patients describe pressure during, and a day or two of soreness after, similar to a small-area liposuction.
The sample is then shipped under controlled conditions to the laboratory, where isolation, characterization, and cryopreservation happen over the following days. You receive documentation of what was stored. From that point, the material sits in storage until you and a physician have an actual clinical reason to retrieve it.
Because a small volume of fat is being removed, the collection is sometimes combined with a procedure that is already harvesting fat — facial fat grafting being the most common pairing in this practice. That is a scheduling and anesthesia efficiency, not a discount on the medical judgment involved.
Where Adipose-Derived Cells Are Actually Used
This is where honest writing on the subject separates from the rest. There is a set of applications with real clinical track records in aesthetic surgery, and a much larger set that is under active investigation. Collapsing the two is how patients end up disappointed.
Established in aesthetic surgery today
Stem-cell-enriched autologous fat grafting is routine work, and Dr. Troell has published long-run outcome series on it. His fifteen-year clinical experience with stem-cell-enriched fat grafting for breast augmentation appeared in the Journal of Clinical Medicine (Troell RJ. J Clin Med. 2025;14(16):5607. DOI 10.3390/jcm14165607) — the evidence is walked through in detail in our guide to fifteen years of breast fat grafting outcomes. His gluteal and hip series, covering optimization and complication avoidance, appeared in Medical Research Archives (Troell RJ. 2026;14(4). DOI 10.18103/mra.v14i4.7467), and informs both the Brazilian Butt Lift and the narrower question of hip dip correction. A related technique — the awake, sedation-based approach to stem-cell-enriched gluteal grafting — is covered in our article on the awake stem-cell-enriched BBL.
In the face, the same principle applies to volume rather than contour. Dr. Troell’s work on permanent composite midface volume replacement, combining implants and stem-cell-enriched fat grafting, appeared in The American Journal of Cosmetic Surgery (Troell RJ. 2026. DOI 10.1177/07488068261440417). Fat grafting also serves as an autologous alternative in breast augmentation for the right candidate, and in reconstruction after breast surgery.
Under investigation, not offered as treatment
Beyond aesthetics, adipose-derived cells are an active research subject in orthopedic and wound-healing contexts — cartilage and joint conditions, fracture healing, burn and post-surgical wound repair. The literature here is genuinely promising and genuinely unsettled: study sizes vary widely, protocols are not standardized, and long-term comparative data is thin.
Two things follow from that, and neither is a technicality. First, these are investigational applications, not established therapies, and no one should bank cells on the assumption that a specific future treatment will exist. Second, they sit outside the scope of a facial plastic and cosmetic surgery practice. Dr. Troell is a facial plastic and cosmetic surgeon; orthopedic and wound-care applications belong to the physicians who treat those conditions, and we will say so plainly rather than imply a service we do not provide.
Want a Straight Answer About Your Own Situation?
A consultation is where general information becomes a specific recommendation — including, sometimes, the recommendation not to proceed.
Does It Matter How Old You Are When You Bank?
You will read everywhere that younger cells are better cells, and that banking early is therefore urgent. The published data is more nuanced than the marketing, and it is worth knowing what it actually shows before anyone uses your age as a reason to hurry you.
The intuitive argument is real enough as biology: proliferative capacity declines with age, and the cumulative effects of illness, medication, and time show up in tissue. Whatever you store is a snapshot of your biology on the day it was collected.
But a peer-reviewed study designed to test exactly this found less age effect than the intuition predicts. Devitt and colleagues examined cell isolation, viability, and growth from human adipose tissue cryopreserved for between 2 and 1,159 days, taken from patients aged 26 to 62. Patient age did not significantly affect stem cell isolation, viability, or growth, and mesenchymal stem cell markers were maintained across every cohort tested (Devitt SM, Carter CM, Dierov R, et al. Stem Cells Int. 2015;2015:146421. DOI 10.1155/2015/146421. PMID 25945096).
The same study did find a duration effect, and an instructive one. Significantly more viable cells were initially isolated from tissue cryopreserved less than a year than from tissue cryopreserved more than two years — but that difference did not persist once the cells were grown out, with no significant differences in viability or growth at the later time points. In other words: long-term cryopreservation is an effective banking method, and the shortfall it produces at isolation appears to be recoverable.
So the honest version is this. Banking earlier is defensible on general biological grounds, and there is nothing wrong with doing it young. But the specific claim that your cells will be unusable if you wait is not what the evidence shows, and it should not be used as a pressure tactic. This is a considered decision, not a same-week one.
What Banking Cannot Promise You
A guide that only lists upside is a sales page. Here is the other column, stated plainly.
It does not guarantee a future treatment will exist. Banking preserves an option. Whether a specific therapy for a specific condition reaches clinical availability, and whether you would be a candidate, is unknown on the day you bank and stays unknown for years.
Stored is not the same as usable. Cryopreservation is well established, and quality assays exist precisely because viability and differentiation capacity have to be verified rather than assumed. Ask any bank what it measures and how often.
A banked, expanded cell product is not automatically legal to administer. As covered above, culture expansion moves the material out of the Section 361 lane. That is a real constraint on what can be done with what you stored, and it is not resolved by having stored it.
Storage is an ongoing commitment. Cryogenic storage is a service with a term, and the material depends on that service continuing. This is a fair question to ask any bank about directly.
Banking is elective and self-pay. It is not a covered medical service, and it should be weighed as the discretionary decision it is.
None of this argues against banking. It argues for banking with clear eyes — which, in a field this crowded with overstatement, is most of the value a surgeon can add.
Why This Practice Answers the Question This Way
Dr. Robert J. Troell has been working with adipose-derived cells since well before the field became a mainstream conversation, and he wrote two of the reference chapters other surgeons learned from.
He is a board-certified facial plastic surgeon, a Diplomate of the American Board of Cosmetic Surgery, and certified by the American Board of Stem Cell and Fat Transfer Physicians — the last of which is the credential that matches this subject directly rather than by adjacency. He completed his training at the University of South Florida and Stanford University, where he later served as a Clinical Professor, and has more than 30 years of surgical experience and 58+ peer-reviewed publications.
The teaching record is the part most relevant here: he has taught 23 hands-on courses to other surgeons in high-definition liposuction with gluteal and breast fat grafting — that is, in the harvesting and grafting techniques that determine whether adipose tissue survives the trip from one place to another. His two chapters in Stem Cells in Aesthetic Procedures: Art, Science, and Clinical Techniques (Springer Berlin Heidelberg, 2014) cover harvesting, processing, and administration (pp. 249–292) and current therapeutic uses (pp. 343–363) respectively. The full record is on the medical publications page, and his background is detailed on his surgeon bio.
The practice is located on South Fort Apache Road in the Spring Valley area of Las Vegas, and consultations for banking candidacy are in person.
Stem Cell Banking: Common Questions
How much fat do I need to provide?
Roughly 25 to 50 cc — about two to three tablespoons — collected through a small cannula during a short office procedure under local anesthesia.
Does the collection procedure hurt?
Most patients describe pressure during the collection and a day or two of soreness afterward, comparable to a small-area liposuction rather than to surgery. It is done under local anesthesia and takes about twenty minutes.
Is stem cell banking FDA approved?
No, and no clinic can honestly claim otherwise. There is no FDA-approved adipose stem cell therapy for cosmetic or orthopedic use. What exists is 21 CFR 1271.10(a), which describes when an autologous, minimally manipulated tissue product is regulated solely under Section 361 of the Public Health Service Act and therefore does not require premarket approval. That is an exemption from approval, not an approval.
How long can my cells stay banked?
Cryopreserved material can remain in storage for years at a properly maintained facility. Published work on adipose tissue cryopreserved for up to 1,159 days found that viable stem cells could still be isolated, that mesenchymal stem cell markers were maintained, and that the lower initial yield seen after longer storage did not persist once the cells were grown out (Devitt SM, et al. Stem Cells Int. 2015;2015:146421). The meaningful question is not how long material can sit there but what the laboratory measures while it does — flow cytometry and differentiation assays are how a bank demonstrates that stored cells retain their capacity rather than assuming it.
Can I use banked cells for both cosmetic and medical purposes later?
Your banked material is yours, but what can legally and appropriately be done with it depends on the regulatory category it falls into and on the physician treating the condition. Cosmetic fat grafting and laboratory-expanded cell products are not the same regulatory object, and orthopedic or wound-care applications belong to the specialists who treat those conditions, not to a cosmetic surgery practice.
Is banking the same thing as a stem-cell-enriched fat transfer?
No. A stem-cell-enriched fat transfer is a same-day surgical procedure in which your own fat is harvested, processed, and immediately grafted where volume is needed. Banking is long-term storage of a small sample for possible later use. They share a source tissue and nothing else.
Am I too old to bank?
There is no cutoff age. The intuitive argument for banking young is that proliferative capacity declines with age — but a study designed to test it found that patient age across a 26-to-62 range did not significantly affect stem cell isolation, viability, or growth (Devitt SM, et al. Stem Cells Int. 2015;2015:146421). Banking earlier is reasonable; being told your cells will be worthless if you wait is not what the evidence shows.
What questions should I ask a stem cell bank?
Four are worth insisting on: is the facility operating under Good Manufacturing and Good Tissue Practice standards; is every individual sample tested for contamination rather than a batch representative; what assays confirm the stored cells retain differentiation capacity; and what happens to your material if the storage agreement lapses. A bank that answers those clearly is telling you something. So is one that does not.
Do I have to bank in order to have fat grafting?
Not at all. The great majority of stem-cell-enriched fat grafting is same-day work using tissue harvested during the same procedure. Banking is a separate, optional decision about the future, and declining it changes nothing about your candidacy for grafting today.
Evidence & Publications
The clinical claims above draw on Dr. Troell’s published work in adipose-derived regenerative surgery and on primary regulatory and peer-reviewed sources. The full publication record is on the medical publications page.
- Troell RJ. Adipose-Derived Stem and Regenerative Cells: Harvesting, Processing, and Administration. In: Stem Cells in Aesthetic Procedures: Art, Science, and Clinical Techniques. Springer Berlin Heidelberg; 2014:249–292. doi:10.1007/978-3-642-45207-9_18
- Troell RJ. Current Therapeutic Uses of Adipose-Derived Stem and Regenerative Cells. In: Stem Cells in Aesthetic Procedures: Art, Science, and Clinical Techniques. Springer Berlin Heidelberg; 2014:343–363. doi:10.1007/978-3-642-45207-9_24
- Troell RJ. Breast Augmentation in Body Contouring Using Autologous Stem Cell-Enriched Fat Grafting: Fifteen-Year Clinical Experience. J Clin Med. 2025;14(16):5607. doi:10.3390/jcm14165607. PMID: 40869433
- Troell RJ. Gluteal & Hip Stem Cell Enriched Fat Grafting (Brazilian Butt Lift): Optimizing Outcomes While Minimizing Complications. Med Res Arch. 2026;14(4). doi:10.18103/mra.v14i4.7467
- Troell RJ. Permanent Composite Midface Volume Replacement: Artefill, Silastic Implants, and Stem Cell Enriched Fat Grafting. Am J Cosmet Surg. 2026. doi:10.1177/07488068261440417
- Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211–228. doi:10.1089/107632701300062859. PMID: 11304456
- Devitt SM, Carter CM, Dierov R, Weiss S, Gersch RP, Percec I. Successful isolation of viable adipose-derived stem cells from human adipose tissue subject to long-term cryopreservation: positive implications for adult stem cell-based therapeutics in patients of advanced age. Stem Cells Int. 2015;2015:146421. doi:10.1155/2015/146421. PMID: 25945096
- U.S. Food and Drug Administration. 21 CFR 1271.10 — Are my HCT/P’s regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do? Code of Federal Regulations, Title 21, Part 1271, Subpart A. ecfr.gov
This article is for general educational purposes and does not constitute medical advice. Adipose stem cell banking is elective storage, not a treatment, and no outcome is implied or guaranteed. Applications described as investigational are not offered as therapy by this practice. Individual candidacy varies; always consult a qualified, board-certified surgeon about your own goals, medical history, and options before making any treatment decision.
Begin Your Journey with Dr. Troell
Schedule a complimentary consultation with Dr. Troell to discuss your goals, explore your options, and receive an honest, expert assessment. No obligation, no pressure.
Mon–Fri, 8:30 AM – 5:00 PM